GNCAQ vs. ALVO, VECT, ATNFW, SXTPW, ACONW, AIMDW, DRTSW, ALVOW, AONCW, and AONC
Should you be buying Genocea Biosciences stock or one of its competitors? The main competitors of Genocea Biosciences include Alvotech (ALVO), VectivBio (VECT), 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Aclarion (ACONW), Ainos (AIMDW), Alpha Tau Medical (DRTSW), Alvotech (ALVOW), American Oncology Network (AONCW), and American Oncology Network (AONC). These companies are all part of the "medical" sector.
Alvotech (NYSE:ALVO) and Genocea Biosciences (NASDAQ:GNCAQ) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, community ranking, analyst recommendations and valuation.
Genocea Biosciences has a net margin of 0.00% compared to Genocea Biosciences' net margin of -967.97%.
Alvotech currently has a consensus price target of $12.67, indicating a potential downside of 10.48%.
Alvotech has a beta of 0.07, suggesting that its share price is 93% less volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 2.31, suggesting that its share price is 131% more volatile than the S&P 500.
In the previous week, Alvotech had 2 more articles in the media than Genocea Biosciences. MarketBeat recorded 2 mentions for Alvotech and 0 mentions for Genocea Biosciences. Genocea Biosciences' average media sentiment score of 0.43 beat Alvotech's score of 0.00 indicating that Alvotech is being referred to more favorably in the media.
Genocea Biosciences has lower revenue, but higher earnings than Alvotech.
Alvotech received 4 more outperform votes than Genocea Biosciences when rated by MarketBeat users.
Summary
Alvotech beats Genocea Biosciences on 5 of the 9 factors compared between the two stocks.
Get Genocea Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNCAQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GNCAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GNCAQ vs. The Competition
Genocea Biosciences Competitors List
Related Companies and Tools
